Clinical Trials Browser

Phase 2 × L-BLP25 × Clear all

NCT00828009 2023-07-07

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2 Completed

70 enrolled 10 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01496131 2018-03-09

Tecemotide (L-BLP25) in Prostate Cancer

Phase 2 Completed

28 enrolled 9 charts

Prostatic Neoplasms

NCT01462513 2018-02-13

LICC

Phase 2 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01507103 2017-01-13

SPRINT

Phase 2 Completed

124 enrolled 9 charts

Gastrointestinal

Carcinoma, Neoplasms, Neoplasms by Site, Rectal Neoplasms

NCT00157209 2015-11-18

Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)

Phase 2 Completed

171 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00157196 2015-08-18

Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

Phase 2 Completed

22 enrolled 6 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms